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Abstract 
The purpose of this study is to survey the relationship between the temperature factor and 
pharmaceutical capitalization returns by analyzing both the daily and weekly frequency data.  
The threshold regression model with the GJR-GARCH process was applied for examination 
in this study; we find that pharmaceutical capitalization returns can be boosted after exposure 
to extremely cold temperatures for a period of time.  Besides, the delayed effect of cold 
weather is demonstrated to exist.  This phenomenon can be illustrated by epidemiological 
evidence-related mental factors, not by traditional behavioral finance.  Lower weekly 
average temperatures are beneficial for investors to gain weekly pharmaceutical 
capitalization returns.  We are of the opinion that our findings offer an insightful suggestion 
for investors to buy pharmaceutical stocks at an opportune moment. 
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1. Introduction 
The pharmaceutical industry is a knowledge-intensive industry where patents play a 
principal role in bringing new products to the market. The main characteristics of this 
industry consist of the following components: high capital input, high failure rates of lab 
products, long return periods, and monopoly protection. Since the 1970s, pharmaceutical 
manufacturing has become greatly concentrated with several large corporations holding a 
ruling position throughout the world and with a few firms making medicines within each 
country, which is due in part to the fact that only large enterprises can afford the high 
expenditures of pharmaceutical research and development (R&D) (Boldrin and Levine, 
2006). The pharmaceutical industry contributes vastly to national health. The research, 
exploitation and effective exertion of drugs have improved many people’s quality of life and 
rescued many lives from the threats of a variety of diseases and injuries. For such an 
important industry, a detailed exploration for its key success factors by the performance of 
pharmaceutical stocks is quite rational.  
A few specific situations that can alter the trend of pharmaceutical stocks have been 
identified in the past. The pharmaceutical sector has had historically parallel or worse 
performance compared with the others in the market indices during the period of the collapse 
of the stock markets (Skrepnek et al. 2007), and potential threats of drug price regulation can 
adversely affect the performance of stock prices and firm-level R&D expenditures (Golec et 
al. 2010). The mean and the volatility of pharmaceutical sector returns will augment if a 
rightist party is about to hold the reins of a government (Bechtel et al. 2010). EU countries 
implement a more rigid pharmaceutical price control than the US, hence the US enterprises 
reap more benefits, spend more on R&D, and gain better stock returns (Golec et al. 2010). 
An important tendency displayed in previous research revealed that enhancement of annual 
medical demand in virtue of demographic changes correlated closely with increases of yearly 
returns of pharmaceutical stocks (Ammann et al. 2011). Negative news induced stronger 
reaction than positive news for pharmaceutical stock returns (Perez-Rodriguez et al. 2012).  
Furthermore, some events or particular conditions were found to be able to make a huge 
impact on an individual pharmaceutical company. Delay announcements of product 
introduction could result in abnormal returns on assets, and further lead to depressed stock 
price performance (Hendricks et al. 2008); on the contrary, there would be a positive market 
reaction to detailed proclamations on innovative activities, especially for proclamations that 
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received extensive media coverage (Koku, 1998).  Exposure of deceptive marketing and 
advertising could cause significant and negative market returns (Wiles et al. 2010; Tipton et 
al. 2009), and direct-to-consumer advertising was related to lower systematic risks and 
higher stock returns (Osinga et al. 2011). U.S. investors castigated non-corporate social 
responsibility (non-CSR) active firms that executed pharmaceutical product recalls, but U.K. 
investors rewarded similar actions adopted by firms which were not ordinarily CSR-active 
(Cheah et al. 2007). Stock market losses from a failure of product approval were much larger 
in proportion than stock market gains from product development successes (Sharma et al. 
2004). Moreover, abnormally large returns caused by Food and Drug Administration’s 
approvals of new drugs were very rare (Perez-Rodriguez et al. 2012). 
For the perspective of the management in drug companies, the drug companies whose 
stocks outmatched the industry often owned better product portfolios and distribution 
(Markovitch et al. 2005), and changes in cash compensation for top managers in the 
pharmaceutical industry were associated with lagged stock returns (Veliyath, 1999). From 
the point of view of the technological aspect, the market values of pharmaceutical firms will 
be raised if they possess higher patent counts, leading patent positions, and more patent 
citations (Chen et al. 2010).  And there is a significant and positive relationship among 
pharmaceutical stock return volatility, R&D intensity and diverse patent related steps 
(Mazzucato et al. 2012).  Walter (2012) reported that pharmaceutical companies could gain 
from both outward and inward licensing, e.g. the patents of some medicament, and then raise 
the returns of their own stocks. 
In spite of the plentiful research results, however, very little of the past literature focused 
on the influence of natural elements, such as temperature changes, on pharmaceutical stocks 
up to now. In fact, a few studies have demonstrated the harmful effects of temperature on 
mortality in the United States, Europe and developing countries (Basu, 2009, Anderson et al. 
2009, Hajat et al. 2005). The effects of temperature upon morbidity outcomes like 
hospitalization, general practitioner consultations and emergency department visits were also 
documented by several other investigations (Green et al. 2010, Gascoigne et al. 2010, 
Knowlton et al. 2009, Schwartz et al. 2004). Episodes of extreme cold weather are relevant 
to peaks in visits of general practice, hospital admissions and cardiovascular events among 
the elderly (Gascoigne et al. 2010), and exposure to extreme heat is related to excess 
morbidity and mortality (Uejio at al. 2011). The noticeable increment of hospitalization rates 
or out-patient department visits will lead to a vast consumption of medical resources, and the 
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expenditures of drugs may increase simultaneously. Accordingly, it seems to be a rational 
deduction that violent conditions of temperature are favorable to the whole pharmaceutical 
industry.  
In the past, few studies indicated that stock market returns could vary due to mood changes 
related to the effects of cold or hot weather (Cao et al. 2005, Chang et al. 2006); the impact 
of temperature may abate in a highly efficient market (Yoon et al. 2009). These researches 
targeted principally on the changes of market indices associated with weather-related 
variables.  For a particular sector of the economy, such as the pharmaceutical industry, the 
relevance of temperature to it remains unclear.  The purpose of this study is to explore the 
relationship between temperature and market capitalization of pharmaceutical stocks. By 
conducting this research, we would like to disclose if certain kinds of news, frequently 
contacted but easily ignored, have the potential to help investors generate profits on 
pharmaceutical stocks.  
By adopting a threshold model with the GJR-GARCH process proposed by Glosten et al. 
(1993) on error terms and stock market data of Taiwan, we attempt to elucidate the impact of 
temperature on Taiwanese pharmaceutical stocks. Based on the assumption that extremely 
cold or hot weather can play a key role in moving the directions of pharmaceutical stock 
prices, dummy variables will be created for those conditions to see if fringe conditions of 
temperature can produce more remarkable effects on pharmaceutical stock returns than 
temperature within a benign range can. It will be able to offer us further discernment for the 
influence of specific weather variables on pharmaceutical stocks. Besides, some time-series 
studies have showed that the exposure to extreme temperature endangers health for a period 
lasting several days since its occurrence (Braga et al. 2001, Gasparrini et al. 2010), hence we 
also investigate whether the delayed effects of environmental stressors for stock market 
returns exist or not. 
 
 
2. Methodology 
2.1  Advanced Nonlinear ESTAR Unit Root Test 
Recently, there is a growing consensus that stock market price indices might be non-linear 
and that the conventional unit root test has lower power in detecting its mean reverting 
(stationary) tendency.  As such, this article employs a newly developed non-linear stationary 
 5 
test advanced by Kapetanios et al. (2003) to determine if the stock market indices of this 
paper are non-linear stationary. 
The KSS nonlinear stationary test is based on detecting the presence of non-stationarity 
against nonlinear but a globally stationary exponential smooth transition autoregressive 
model (ESTAR) process: 
tttt YYY    )]exp(1[
2
11                                           (1) 
where tY  is the data series of the variable considered, t  is an independently identically 
distributed (i.i.d.) error with a zero mean and constant variance, and 0  is known as the 
transition parameter or smooth parameter of the ESTAR model that governs the speed of 
transition.  We are now interested in testing the null hypothesis of 0  against the 
alternative of 0 .  Under the null hypothesis, tY  follows a linear unit root process, 
whereas it’s a nonlinear stationary ESTAR process under the alternative. However, the 
parameter   isn’t indentified under the null hypothesis.  Kapetanios et al. (2003) followed 
Luukkonen et al. (1988) to compute a first-order Taylor series approximation to the 
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Then, the null hypothesis and alternative hypothesis are expressed as 0  (non 
stationarity) against 0  (nonlinear stationarity). 
 
2.2  Threshold Model with the GJR-GARCH Process 
In order to examine the “asymmetric” or “non-linear” effects from the daily and weekly 
average temperatures upon the daily and weekly returns of total market capitalization of 
pharmaceutical companies in Taiwan, we employed the non-linear threshold model with the 
GJR-GARCH (1,1) process proposed by Glosten et al. (1993) to investigate the relationships 
between the temperature and pharmaceutical stock returns.  While the previous literature 
focused on the linear models, we firmly believe that the non-linear model is a better method 
to examine the relationships at the heart of our article.  We first used the traditional linear 
model to test the general relationships between the temperatures and pharmaceutical stock 
returns, and then further examined the issue by using the non-linear threshold model. 
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Furthermore, to answer whether the threshold effects of extreme lagged temperatures for 
the total market capitalization returns of pharmaceutical companies subsisted or not, the 
AR(1) model with the GJR-GARCH (1,1) process modified from the models developed by 
Narayan et al. (2011) was employed to explore the relationship between the temperature and 
the  market capitalization returns of pharmaceutical companies, the model in our article was 
set as follows: 
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where tR  and itR   represented the contemporaneous and lagged returns of market 
capitalization of nine pharmaceutical companies in Taiwan, respectively.  l  = 1 and 2, 
represented the daily and weekly frequency data, respectively.  *tT  represented the daily 
and weekly temperatures while *t  represented period 1t  to period 7t  for the daily 
frequency data (one trading day lagged until seven trading days lagged) but period t  for 
weekly frequency data in Taipei City with the time lag of the trading day which had to be 
considered, and tMR  ,  and ktMR  ,  represented the contemporaneous and lagged returns of 
the stock market.  Both I  and I  were the dummy variables, 1I  when *tT  was 
above ic  or r , while 1
I  when *tT  was below ic  or r , and ic  and r  denoted the 
unknown threshold values for the daily and weekly temperatures, respectively.
1
  Since a 
dummy variable was not an economically elucidative variable, we converted the temperature 
into one in order to make sure that the temperature threshold set by us can be an appropriate 
divide between the lower temperature and higher temperature.  t  was the residual of the 
white-noise disturbance, 1 t  was the information set on period 1t , 1tI  was also the 
dummy variable, where 11 tI  when 1t  was below 0 and 01 tI  when 1t  was 
above 0.  Several restrictions on the above equations should be noted: 0 , 0 , 0  
                                                 
1
 The threshold value was endogenously determined by using the Chan’s (1993) grid search method to find the 
consistent estimate of the threshold.  This method arranged the values, { *tT }, in an ascending order and 
excluded the smallest and largest 15 percent, and the consistent estimate of the threshold was the parameter 
that yielded the smallest residual of sum squares (RSS) over the remaining 70 percent. 
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and 0  .  If   was significant ( 0 ), there would be an asymmetric effect on the 
conditional heteroskedasticity variance. 
The reason for adopting the GJR-GARCH model as opposed to EGARCH in our article 
was due to the fact that the parameterization of the GJR-GARCH model made it the more 
promising approach. (please refer to Nelson, 1991, Engle and Ng, 1993, Glosten et al., 1993, 
and Chang et al., 2006). 
 
 
3. Data 
The definition of a pharmaceutical company is a company that sells and produces 
pharmaceuticals as its major business items.  This study was conducted by using nine major 
pharmaceutical companies in Taiwan.
2
  Our original data for the market capitalization of the 
nine pharmaceutical companies and the closing price indices of Taiwan Stock Exchange 
Corporation (TSEC) Weighted Index were obtained from the database of Taiwan Economic 
Journal (TEJ) and the websites of Taiwan Stock Exchange Corporation, and the data of the 
average temperatures in Taipei City, which were measured in degrees Celsius, were gained 
from the Central Weather Bureau of Taiwan (CWB).  The entire sample period was from 
January 1, 2004 to December 31, 2010 for a total of 1732 daily frequency observations and 
357 weekly frequency observations.  The total market capitalization of these nine 
corporations was used to reflect the changes of the whole pharmaceutical industry, which 
were recorded day by day.  The daily and weekly returns of the market capitalization of the 
nine pharmaceutical companies and the daily and weekly returns of the TSEC Weighted 
Index were calculated as follows: 
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Where 
i
tR  represented the daily and weekly returns of the total market capitalization of the 
nine pharmaceutical companies, 
i
tIPln  were logarithms of the daily and weekly frequency 
                                                 
2
 The nine pharmaceutical companies are as follows: China Chemical & Pharmaceutical Co., Ltd. (C.C.P.C), 
Standard Chemical & Pharmaceutical Co., Ltd. (S.C.P.C), Maywufa Co., Ltd. (MAYWUFA), Sinphar 
Pharmaceutical Co., Ltd. (SINPHAR), TTY Biopharm Co., Ltd. (TTY), Chi Sheng Chemical Corp. (CHI 
SHENG), Synmosa Biopharma Corp. (SYNMOSA), Orient Europharma Co., Ltd. (ORIENT 
EUROPHARMA), and Center Laboratories, Inc. (CENTER LAB.) 
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data of the market capitalization of the nine pharmaceutical companies, and j
tMR ,  
represented the daily and weekly returns of the TSEC Weighted Index, and j
tMIP ,ln  were 
logarithms of the daily and weekly data of TSEC Weighted Index.  Table 1 presented the 
summary statistics for all the variable series in our study, and the results of Table 1 showed 
that the series data exhibit skewness and excess kurtosis relative to the normal distribution, 
and they did not conform to the normal distribution at the 1 % level of significance by using 
the Jarque-Bera test; the serial auto-correlation with significance up to 24 lags existed in all 
of the variables at the 10 % level by using the Ljung-Box Q test.  Figures 1 to 3 showed the 
time trends of all the series, Figures 4 to 6 showed the volatilities of all the series,
3
 and from 
Figures 4 and 5, there was substantial increase in the volatilities of returns of the total market 
capitalization of the nine pharmaceutical companies and the TSEC Weighted Index (daily and 
weekly) during the period between the second half of 2007 and the first half of 2009, which 
showed that higher and persistent fluctuations could be observed since the eruption of the 
Subprime Mortgage Crisis. 
 
 
4. The Empirical Results 
The results of the three traditional unit root tests, Augmented Dickey and Fuller (ADF; 
1984), Phillips and Perron (PP; 1988) and Kwiatkowski et al. (KPSS; 1992), were 
summarized in Table 2.  The results of Table 2 showed that all the variables were the )0(I  
type series at the 1% significance level.  Table 3 represented the results of the KSS (2003) 
nonlinear ESTAR unit root test, which shows that all of the variables in this study were 
nonlinear )0(I  series at the 1% significance level. 
Tables 4 and 5 represented the results of linear regression between the pharmaceutical 
capitalization returns and temperature factors for the daily data and weekly data, respectively.  
The results of Table 4 represented that there were non-significant linear relationships 
between the pharmaceutical capitalization returns and temperature factors on period 1t  
(one trading day lag) to period 7t  (seven trading days lag), and Table 5 represented that 
there was also a non-significant linear relationship between the market capitalization returns 
of the nine pharmaceutical companies and temperature factors for the weekly data.  Since 
                                                 
3
 The volatilities of the returns of market capitalization of the nine pharmaceutical companies, the returns of the 
TSEC Weighted Index and the average temperatures are measured by the conditional variances from the 
ARMA(p,q)-GARCH(1,1) model, the lag-lengths of the ARMA(p,q) model selected by minimizing AIC. 
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the results in Tables 4 and 5 showed that the temperature factors did not have a significant 
influence on the pharmaceutical capitalization returns, which showed that the real 
relationships between the pharmaceutical capitalization returns and temperature factors could 
not be clarified by using the linear regression model, accordingly, the threshold regression 
method with the GJR-GARCH model was applied to examine the relationships between the 
market capitalization returns and temperature factors in our study. 
Table 6 represented the results of the threshold model for the daily data.  First, from the 
coefficients of dailytR 1 , 
daily
tMR  , , 
daily
tMR 1 ,   and 
daily
tMR 2 ,   in this table, it was evident that the stock 
market returns had strong effects on the capitalization returns of the nine pharmaceutical 
companies, which might be partly explained by the price limits in the Taiwan stock market.  
These results were highly consistent with those reported in previous studies, thus signifying 
that strong auto-correlations existed in the market capitalization returns of the pharmaceutical 
companies.   Moreover, from Table 6, when the daily average temperatures were above the 
threshold values of 9.80 C0 , 9.30 C0  and 11.40 C0 , the coefficients were -2.1809e-05, 
-3.3465e-05 and -6.0412e-06 on periods 1t , 3t  and 4t , respectively.  And when 
the daily average temperatures were below the threshold values, the coefficients were 
4.9791e-04, 0.0108 and 8.9227e-04 on periods 1t , 3t  and 4t , respectively.  The 
results of Table 6 showed that the temperature factors had a non-significant negative 
influence on the market capitalization returns of the pharmaceutical companies when the 
daily average temperatures were above the threshold values, and the temperature factors had 
a significant positive influence on the market capitalization returns of the pharmaceutical 
companies when the daily average temperatures were below the threshold values.  In 
addition, by further observations of the AF  statistics in Table 6, the statistics were 4.7245, 
12.3788 and 8.6195 on periods 1t , 3t  and 4t , respectively.  Therefore, we found 
that the asymmetric relationships truly existed between the daily average temperatures and 
the market capitalization returns of the pharmaceutical companies at the 5% significance 
level, which showed that the temperature factors had significant asymmetric or threshold 
effects on the market capitalization returns of the pharmaceutical companies on periods 1t , 
3t  and 4t . 
Table 7 represented the results of the GJR-GARCH (1,1) model for the daily data, 
according to Bollerslev (1986) and Glosten et al. (1993),   reflected the impact of past 
variance on the market capitalization returns of the nine pharmaceutical companies, and   
could be viewed as the “good news” coefficient, with higher values implying that more 
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recent good news had a greater impact on the market capitalization returns, and   could be 
viewed as the “bad news” coefficient, with higher values implying that more recent bad news 
had a greater impact on the market capitalization returns, while    measured the 
persistence of volatility, and the results in Table 7 indicated that both   and   were 
significant at the 1% significance level.  In addition, the significant test statistics for the   
coefficient on period 4t  further indicated that the asymmetric effect existed in the 
conditional variance model in our study. 
Table 8 represented the results of the threshold model for the weekly data, which showed 
that when the weekly average temperature was above the threshold value of 12.214 C0 , the 
temperature factor would have a significant negative influence (-0.00068) on pharmaceutical 
capitalization returns, and the temperature factor would have significant positive influence 
(0.0052) on pharmaceutical capitalization returns when the weekly average temperature was 
below the threshold value.  The AF  statistic in Table 8 was 8.8589, which showed that the 
temperature factor also had a significant threshold effect on the market capitalization returns 
of the nine pharmaceutical companies for the weekly frequency data. 
Table 9 represented the results of the GJR-GARCH (1,1) model for the weekly data, which 
showed that both   and   were significant at the 1% significance level, and the 
significant test statistics for the   coefficient further indicated that the asymmetric effect 
also existed in the conditional variance model for the weekly data.  The conditional 
volatility on the market capitalization returns of the pharmaceutical companies tended to be 
higher when the news of the weather was unfavorable.  A possible explanation for this 
phenomenon was that investors (especially institutional investors) tended to be more 
pessimistic and they would sell a lot of pharmaceutical stocks when unexpected negative 
weather information, e.g. microtherm, arrived in the market for fear of a further loss.  
However, other investors expected that the lower temperature would cause the occurrence of 
several peaks of doctor visits and medicine consumptions, and they would buy 
pharmaceutical stocks at this moment.  Thus, the volatilities of trading volumes and stock 
return would tend to be higher. 
 
 
5. Conclusion and Discussion 
Past literature in the field of epidemiology indicated that once people were attacked by low 
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temperatures, there would be a notable increase in all-cause mortality after a period of 
several days.  In addition, the degree of increase in all-cause mortality was in proportion to 
the degree of decrease in mean temperature (Hashizume et al. 2009, McMichael et al. 2008).  
Under a low temperature environment, the mortality would be raised over a shorter lag 
period (0 - 1day) and a longer lag period (0-13 days), and the most obvious effects of 
microtherm appeared at lags 3 - 4 days (Hashizume et al. 2009).  
The aforementioned reports offer us good clues to establish our ratiocination. Tremendous 
increment of morbidity and mortality in cold weather may lead to depletion of a great volume 
of medical resources and then boost pharmaceutical stock returns.  The area of Taiwan is 
only about 14400 square miles; when a low temperature occurs in Taipei City, a nationwide 
low ambient temperature often betides simultaneously. It will uplift the incidence of 
country-wide deaths and diseases; therefore, both visits of emergency departments and 
general practice and hospitalization will rise in a short period of time, which will bring about 
great consumption of medicine.  This phenomenon can be easily observed by employees of 
medical institutions, drug companies, Bureau of National Health Insurance (BNHI) and other 
corporations familiar with the pharmaceutical industry.  
Various diseases can be induced after exposure to extremely low temperatures, and 
different clinical onsets of a variety of symptoms will result in several peaks of doctor visits 
and medicine usage. They will lead to persistent increment of revenues of pharmaceutical 
firms in the next few days after the arrival of cold weather.  Corporations choose to buy 
pharmaceutical stocks consecutively during this period because they expect that the revenues 
of pharmaceutical companies can benefit from severe cold.  Their purchase behavior 
contributes to the increase of the market values of pharmaceutical stocks, which makes 
pharmaceutical stock returns move up more than once, hence the effect of bitter cold upon 
pharmaceutical shares can be observed over a lag of several days.  This delayed effect can 
not be efficaciously clarified in terms of traditional behavioral finance, but it can be realized 
from the viewpoint of epidemiological evidence-related mental factors. 
Compared with a very low daily mean temperature, a lower weekly average temperature 
exerts a similar influence on pharmaceutical stocks in the meantime.  It may suggest a 
sustained lower but not too low temperature is enough to increase morbidity and revenues of 
pharmaceutical companies.  This phenomenon attracts visions of corporations, and then buy 
orders emerge in large numbers.  To verify our conjecture that the incomes of 
pharmaceutical firms can derive benefits both from a single bitter cold day and a chilly 
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period lasting for several days, a detailed shipment record of this industry is necessary, but it 
can not be acquired for the moment. 
In terms of meteorological economics, temperature is an everlasting factor in our 
environment.  It is hard to manipulate, but its impact on our life can be predicted. The 
duration and the onset of an extreme temperature can be roughly estimated by a weather 
forecast, so we are able to pursue the good and evade the evil through the messages broadcast 
in the mass media.  An extreme temperature not only changes people’s mental states but 
also destroys human bodies’ homeostasis.  It elevates medical demand and then pushes the 
supply of medicine to increase.  Having a good command of knowledge about 
weather-related laws of demand and supply can help people make a more precise investment. 
We contribute to current literature by proving that some kinds of natural elements, like 
temperature can alter the trend of pharmaceutical stocks.  The outcome of our study may be 
strongly associated with the increment of temperature-related morbidity and mortality.  We 
have some practical suggestions for institutional investors of pharmaceutical stocks. In a 
small populous country with many domestic market oriented drug companies, when an 
extremely low temperature is about to prevail over the whole country and a bullish stock 
market is expected to begin, institutional investors should pay attention to medical news and 
buy pharmaceutical stocks. These shares must be held for 3 to 4 days after the end of a cold 
current.  This strategy can help institutional investors earn more profits.  We deem that 
careful observation of sales of cold resistance equipment is beneficial to institutional 
investors’ decisions. 
 
Table 1. Summary statistics 
 
daily
tT  
weekly
tT  
daily
tR  
weekly
tR  
daily
tMR  ,  
weekly
tMR  ,  
Mean 23.59 23.54 0.00082 0.0040 0.00023 0.00102 
Max. 32.80 32.07 0.1149 0.2116 0.0652 0.0941 
Min.  9.30 10.93 -0.0731 -0.1672 -0.0691 -0.1126 
S. D. 5.2645 4.9576 0.0203 0.0480 0.0140 0.0305 
Skewness -0.3524*** -0.2383* 0.1622*** 0.2696** -0.4221*** -0.7720*** 
Kurtosis 0.8426** 1.0818** 2.5087* 3.3958** 3.1145* 1.6371* 
Jarque-Bera 87.136*** 20.845*** 461.77*** 175.86*** 751.45*** 75.333*** 
L-B Q (24) 53.594*** 48.930*** 34.389* 33.897* 38.601** 36.211* 
Obs. 1732 357 1732 357 1732 357 
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Notes: 1. 
daily
tT  and 
weekly
tT  denoted daily and weekly average temperatures in Taipei City, respectively. 
daily
tR  and 
weekly
tR  denoted daily and weekly returns of the market capitalization of the nine 
pharmaceutical companies in Taiwan, respectively, and 
daily
tMR  , and 
weekly
tMR  , denoted daily and weekly 
returns of the TSEC Weighted Index, respectively. 
2. *, ** and *** denoted significance at 10%, 5% and 1% significance levels, respectively. 
3. Jarque-Bera was the statistic of the normal test. 
4. L-B Q was the statistics of Ljung-Box Q. 
 
 
Figure 1. Daily and Weekly Returns of the Total Market Capitalization of the Nine Pharmaceutical 
Companies 
 
Figure 2. Daily and Weekly Returns of the TSEC Weighted Index 
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Figure 3. Daily and Weekly Average Temperatures in Taipei City 
 
 
 
Figure 4. The Volatilities of Daily and Weekly Returns of the Total Market Capitalization of the Nine 
Pharmaceutical Companies 
 
 
Figure 5. The Volatilities of Daily and Weekly Returns of the TSEC Weighted Index 
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Figure 6. The Volatilities of Daily and Weekly Average Temperatures in Taipei City 
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Table 2. Results of Various Unit Root Tests 
 ADF PP KPSS 
daily
tT  -17.2314 (5)*** -36.6190*** 0.0793 
weekly
tT  -16.4603 (6)*** -34.5620*** 0.0902 
daily
tR  -14.5142 (5)*** -29.8737*** 0.1527 
weekly
tR  -14.9672 (7)*** -31.4268*** 0.1099 
daily
tMR  ,  -13.8640 (5)*** -30.4380*** 0.1839 
weekly
tMR  ,  -15.1311 (6)*** -30.3007*** 0.1957 
Notes: 1. *** denote significance at 1% significance level, the numbers in the parentheses were the appropriate 
lag-lengths selected by minimizing AIC. 
2. The critical values for the 10%, 5% and 1% significance levels of ADF, PP and KPSS were 
(-2.567948, -2.863659, -3.435402), (-2.567944, -2.863651, -3.435385) and (0.3470, 0.4630, 0.7390), 
respectively. . 
3. The null hypothesis of ADF and PP was non-stationary (unit root); the null hypothesis of KPSS was 
stationary (non unit root). 
 
 
Table 3. Results of the Nonlinear Unit Root Test –the KSS Test 
 t Statistics on ˆ  
daily
tT  -17.5471 (2)*** 
weekly
tT  -15.7514 (2)*** 
daily
tR  -19.5173 (2)*** 
weekly
tR  -18.3522 (3)*** 
daily
tMR  ,  -16.8273 (3)*** 
weekly
tMR  ,  -17.2011 (2)*** 
Notes: 1. The numbers in the parentheses were the appropriate lag-lengths selected by minimize AIC. 
2. The simulated critical values for different Ks were tabulated in Kapetanios et al. (2003). 
      3. *** denoted significance at the 1% significance level. 
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Table 4. Linear Models to test the General Relationship between the Market Capitalization Returns and Temperatures for the Daily 
Data 
 period 1t  period 2t  period 3t  period 4t  period 5t  period 6t  period 7t  
constant -0.00116 
(0.5387) 
-0.00215 
(0.2543) 
-0.00048 
(0.7981) 
-0.00089 
(0.6389) 
-0.00157 
(0.4070) 
-0.00086 
(0.6503) 
-0.00157 
(0.4054) 
daily
tR 1  0.0632*** 
(0.0088) 
0.0630*** 
(0.0090) 
0.0633*** 
(0.0088) 
0.0636*** 
(0.0085) 
0.0633*** 
(0.0088) 
0.0632*** 
(0.0089) 
0.0632*** 
(0.0089) 
daily
tR 2  0.03686 
(0.1259) 
0.0365 
(0.1290) 
0.0370 
(0.1241) 
0.0367 
(0.1282) 
0.0371 
(0.1241) 
0.0371 
(0.1241) 
0.0366 
(0.1288) 
daily
jtT   0.000072 
(0.3521) 
0.000114 
(0.1420) 
0.000044 
(0.5738) 
0.000061 
(0.4347) 
0.000090 
(0.2495) 
0.000060 
(0.4429) 
0.000091 
(0.2473) 
daily
tMR  ,  0.7859*** 
(0.0000) 
0.7862*** 
(0.0000) 
0.7857*** 
(0.0000) 
0.7859*** 
(0.0000) 
0.7864*** 
(0.0000) 
0.7859*** 
(0.0000) 
0.7863*** 
(0.0000) 
daily
tMR 1 ,   0.0345 
(0.3236) 
0.0351 
(0.3145) 
0.0342 
(0.3272) 
0.0342 
(0.3270) 
0.0348 
(0.3190) 
0.0346 
(0.3223) 
0.0348 
(0.3187) 
daily
tMR 2 ,   0.0184 
(0.5961) 
0.0188 
(0.5878) 
0.0179 
(0.6068) 
0.0183 
(0.5983) 
0.0185 
(0.5951) 
0.0182 
(0.6009) 
0.0190 
(0.5847) 
Note: 1. *, ** and *** denoted significance at the 10%, 5% and 1% significance levels, respectively.  Numbers in parentheses are the p-values. 
     2. The threshold model for the temperature: 
          
0
 ,
1
t
m
k
daily
ktMk
daily
jtj
daily
it
n
i
i
daily
t RTRR   



7.......3 ,2 ,1j  
Where 
daily
tR  represented the daily returns of the market capitalization of the nine Taiwanese medicinal and pharmaceutical industries, 
daily
tT  represents the daily 
average temperature factor variable, 7.......3 ,2 ,1j , represented the temperature factors on period 1t  (one trading day lag) until on period 7t  (seven 
trading days lag), and 
daily
tMR  ,  represented the daily returns of the TSEC Weighted Index. 
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Table 5. Linear Model to test the General Relationship between the Market 
Capitalization Returns and Temperatures for the Weekly Data 
 Coefficients and Statistics 
constant -0.0117 
(0.3511) 
weekly
tR 1  0.0444 
(0.3225) 
weekly
tR 2  0.0812* 
(0.0776) 
tT  0.00061 
(0.2292) 
weekly
tMR  ,  0.8284*** 
(0.0000) 
weekly
tMR 1 ,   0.2455*** 
(0.0035) 
weekly
tMR 2 ,   0.0131 
(0.8761) 
Note: 1. *, ** and *** denoted significance at the 10%, 5%, and 1% significance levels, respectively.  
Numbers in parentheses were the p-values. 
     2. The threshold model for the temperature: 
          
0
 ,1
1
t
q
k
weekly
ktMk
weekly
t
p
i
weekly
iti
weekly
t RTRR   



  
Where 
weekly
tR  represented the weekly returns of the market capitalization of the nine Taiwanese medicinal 
and pharmaceutical industries, 
weekly
tT  represented the weekly average temperature factor variable, and 
weekly
tMR  ,  represented the weekly returns of the TSEC Weighted Index. 
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Table 6. The Threshold Model of the Temperature for the Daily Data 
 period 1t  period 2t  period 3t  period 4t  period 5t  period 6t  period 7t  
constant 6.8739e-04 
(0.5824) 
1.5678e-03 
(0.2673) 
1.0164e-03 
(0.3883) 
3.0263e-04 
(0.8001) 
1.2003e-03 
(0.3077) 
1.5179e-03 
(0.2044) 
1.3845e-03 
(0.2354) 
daily
tR 1  0.0682*** 
(0.0016) 
0.0693*** 
(0.0021) 
0.0685*** 
(0.0021) 
0.0712*** 
(0.0013) 
0.0690*** 
(0.0025) 
0.0696*** 
(0.0023) 
0.0695*** 
(0.0014) 
daily
tR 2  5.6327e-03 
(0.8269) 
5.7025e-03 
(0.8224) 
5.2297e-03 
(0.8326) 
9.1634e-03 
(0.7241) 
7.4525e-03 
(0.7735) 
5.8699e-03 
(0.8192) 
5.7006e-03 
(0.8262) 

 t
daily
jt IT  -2.1809e-05 
(0.6675) 
-3.0813e-05 
(0.5404) 
-3.3465e-05 
(0.4852) 
-6.0412e-06 
(0.9016) 
-3.4209e-06 
(0.9864) 
-5.5567e-05 
(0.2589) 
8.8642e-05 
(0.7521) 

 t
daily
jt IT  4.9791e-04* 
(0.0525) 
-6.6528e-05 
(0.2902) 
0.0108*** 
(0.0005) 
8.9227e-04*** 
(0.0051) 
-4.1625e-05 
(0.3913) 
7.5145e-04 
(0.2800) 
-6.9913e-05 
(0.2210) 
daily
tMR  ,  0.6050*** 
(0.0000) 
0.6035*** 
(0.0000) 
0.6064*** 
(0.0000) 
0.6059*** 
(0.0000) 
0.6033*** 
(0.0000) 
0.6035*** 
(0.0000) 
0.6045*** 
(0.0000) 
daily
tMR 1 ,   0.0517* 
(0.0608) 
0.0486* 
(0.0778) 
0.0493** 
(0.0490) 
0.0505** 
(0.0439) 
0.0515* 
(0.0509) 
0.0504* 
(0.0710) 
0.0564** 
(0.0197) 
daily
tMR 2 ,   0.0581** 
(0.0271) 
0.0550** 
(0.0378) 
0.0528** 
(0.0428) 
0.0563** 
(0.0283) 
0.0549** 
(0.0360) 
0.0561** 
(0.0322) 
0.0573** 
(0.0288) 
CF  5.7637* 
(0.0560) 
1.7447 
(0.4180) 
12.7951*** 
(0.0017) 
9.0921*** 
(0.0106) 
0.7435 
(0.6895) 
2.9628 
(0.2273) 
1.8213 
(0.4023) 
AF  4.7245** 
(0.0297) 
1.6371 
(0.2007) 
12.3788*** 
(0.0004) 
8.6195*** 
(0.0033) 
0.0366 
(0.8484) 
1.3733 
(0.2413) 
0.3321 
(0.5644) 
  9.80 28.60 9.30 11.40 32.20 17.80 32.30 
Note: 1. CF  and AF  denoted that the F-statistics for the null hypothesis were 0,2,1  jj   and symmetric adjustment ( jj ,2,1   ).   was the estimated threshold 
value of the average temperature. 
     2. *, ** and *** denoted significance at the 10%, 5% and 1% significance levels, respectively.  Numbers in parentheses are the p-values. 
     3. The threshold model for the temperature: 
          
0
 ,,2,1
1
t
m
k
daily
ktMkt
daily
jtjt
daily
jtj
daily
it
n
i
i
daily
t RITITRR   







7.......3 ,2 ,1j  
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Table 7. The Results from the GJR-GARCH Model of the Temperature for Daily Data 
 period 1t  period 2t  period 3t  period 4t  period 5t  period 6t  period 7t  
constant 3.1204e-06*** 
(0.0001) 
3.2037e-06*** 
(0.0000) 
3.1047e-06*** 
(0.0001) 
3.2469e-06*** 
(0.0001) 
3.2564e-06*** 
(0.0001) 
3.2834e-06*** 
(0.0000) 
3.1320e-06*** 
(0.0001) 
1th  0.8688*** 
(0.0000) 
0.8662*** 
(0.0000) 
0.8707*** 
(0.0000) 
0.8619*** 
(0.0000) 
0.8626*** 
(0.0000) 
0.8609*** 
(0.0000) 
0.8605*** 
(0.0000) 
2
1t  0.1063*** 
(0.0000) 
0.1092*** 
(0.0000) 
0.1039*** 
(0.0000) 
0.1121*** 
(0.0000) 
0.1120*** 
(0.0000) 
0.1148*** 
(0.0000) 
0.1198*** 
(0.0000) 
1
2
1  tt I  0.0368 
(0.1122) 
0.0366 
(0.1165) 
0.0358 
(0.1091) 
0.0398* 
(0.0869) 
0.0385 
(0.1137) 
0.0369 
(0.1196) 
0.0301 
(0.2219) 
Note: 1. *, ** and *** denoted significance at the 10%, 5% and 1% significance levels, respectively. Numbers in parentheses were the p-values. 
2. The GJR-GARCH model for the temperature: 
            1
2
1
2
11   ttttt Ihh   
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Table 8. The Threshold Model of the Temperature for the Weekly Data 
 Coefficients and Statistics 
constant 0.0171*** 
(0.0018) 
weekly
tR 1  0.0561 
(0.2423) 
weekly
tR 2  0.03654 
(0.4393) 
ITt  -0.00077*** 
(0.0004) 
ITt  0.0054*** 
(0.0081) 
weekly
tMR  ,  0.7405*** 
(0.0000) 
weekly
tMR 1 ,   0.1317** 
(0.0277) 
weekly
tMR 2 ,   -0.0156 
(0.7453) 
CF  22.0177*** 
(0.0000) 
AF  8.6945*** 
(0.0032) 
  12.214 
Note: 1. CF  and AF  denoted that the F-statistics for the null hypothesis were 021    and  
symmetric adjustment (
21   ).   was the estimated threshold value. 
     2. *, ** and *** denoted significance at the 10%, 5% and 1% significance levels, respectively. 
Numbers in parentheses were the p-values. 
     3. The threshold model for the temperature: 
          
0
 ,21
1
t
q
k
weekly
ktMkt
weekly
tt
weekly
t
p
i
weekly
iti
weekly
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Table 9. The Results from the GJR-GARCH Model of the Temperature for the 
 Weekly Data 
 Coefficients and Statistics 
constant 0.000055 
(0.1347) 
1th  0.4315*** 
(0.0000) 
2
1t  0.6767*** 
(0.0006) 
1
2
1  tt I  0.7639** 
(0.0279) 
Note: 1. *, ** and *** denoted significance at the 10%, 5% and 1% significance levels, respectively.  
Numbers in parentheses were the p-values. 
2. The GJR-GARCH model for the temperature: 
          1
2
1
2
11   ttttt Ihh 
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